As described in previous sections, recent studies have shown that PD‐L1 and CTLA4 disrupt the effector function of CTLs, leading to the development of ICI, in which antibodies target these suppressive molecules, as a novel anti‐cancer treatment. Here, CTLA4 is linked to cancer.